Format

Send to

Choose Destination
Breast Cancer Res Treat. 2015 Dec;154(3):533-41. doi: 10.1007/s10549-015-3631-9. Epub 2015 Nov 14.

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.

Author information

1
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. tara.sanft@yale.edu.
2
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. bilge.aktas@yale.edu.
3
BioTheranostics, Inc., 9640 Towne Centre Drive, Suite 200, San Diego, CA, 92121, USA. brock.schroeder@biotheranostics.com.
4
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. veerle.bossuyt@yale.edu.
5
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. michaeal.digiovanna@yale.edu.
6
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. maysa.abu-khalaf@yale.edu.
7
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. gina.chung@yale.edu.
8
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. andrea.silber@yale.edu.
9
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. erin.hofstatter@yale.edu.
10
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. sarah.mougalian@yale.edu.
11
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. lianne.epstein@yale.edu.
12
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. christos.hatzis@yale.edu.
13
BioTheranostics, Inc., 9640 Towne Centre Drive, Suite 200, San Diego, CA, 92121, USA. cathy.schnabel@biotheranostics.com.
14
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. lajos.pusztai@yale.edu.

Abstract

Extended adjuvant endocrine therapy (10 vs. 5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer; however, the absolute benefit is modest, and toxicity and tolerability challenges remain. Predictive and prognostic information from genomic analysis may help inform this clinical decision. The purpose of this study was to assess the impact of the Breast Cancer Index (BCI) on physician recommendations for extended endocrine therapy and on patient anxiety and decision conflict. Patients with stage I-III, ER-positive breast cancer who completed at least 3.5 years of adjuvant endocrine therapy were offered participation. Genomic classification with BCI was performed on archived tumor tissues and the results were reported to the treating physician who discussed results with the patient. Patients and physicians completed pre- and post-test questionnaires regarding preferences for extended endocrine therapy. Patients also completed the validated traditional Decisional Conflict Scale (DCS) and State Trait Anxiety Inventory forms (STAI-Y1) pre- and post-test. 96 patients were enrolled at the Yale Cancer Center [median age 60.5 years (range 45-87), 79% postmenopausal, 60% stage I). BCI predicted a low risk of late recurrence in 59% of patients versus intermediate/high in 24 and 17%, respectively. Physician recommendations for extended endocrine therapy changed for 26% of patients after considering BCI results, with a net decrease in recommendations for extended endocrine therapy from 74 to 54%. After testing, fewer patients wanted to continue extended therapy and decision conflict and anxiety also decreased. Mean STAI and DCS scores were 31.3 versus 29.1 (p = 0.031) and 20.9 versus 10.8 (p < 0.001) pre- and post-test, respectively. Incorporation of BCI into risk/benefit discussions regarding extended endocrine therapy resulted in changes in treatment recommendations and improved patient satisfaction.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02057029.

KEYWORDS:

Anxiety; Hormone therapy; Late recurrence; Risk assessment; Satisfaction; Survivorship

PMID:
26578401
PMCID:
PMC4661200
DOI:
10.1007/s10549-015-3631-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center